Pursuing Next-Generation Therapies
Effective therapies are needed to treat inflammatory and fibrotic diseases. Even with recent advances, many people still have few treatment options and continue to experience symptoms and disease progression.
Our Expertise
Our advanced immunology research is unlocking next-generation therapies for inflammatory and fibrotic diseases such as primary biliary cholangitis (PBC), inflammatory bowel disease, and lupus.
Leveraging our network of partnerships and extensive expertise in immunology, we're advancing a range of programs to help address these chronic conditions and the toll they take on patients’ lives.
Advancing Options for Primary Biliary Cholangitis
PBC is a rare, chronic, autoimmune disease that primarily affects women and can cause liver damage and possible liver failure if left untreated. The disease currently has no cure. More than half of people diagnosed are asymptomatic, but symptoms such as pruritus (chronic skin itching) can be invisible, debilitating and severely affect health-related quality of life. The journey to a PBC diagnosis can be long and challenging.
Building on our treatment advances that help address both symptoms and disease progression, we are relentlessly committed to providing more options so patients don’t have to settle for treatments that may not address symptoms impacting their health-related quality of life.
Rheumatology
Pulmonology
Dermatology
Hepatology
Gastroenterology
Our Scientific Approach
Chronic inflammatory and fibrotic diseases are often characterized by a vicious cycle of tissue damage, immune response and fibrosis (scarring) that leads to organ damage and disease progression over time. Our programs focus on disrupting that cycle through four different methods, which we call our BETR framework:
PIPELINE
Clinical Trials
We're committed to involving the communities most impacted by disease in the design and execution of our clinical trials.
Medicines
We have developed more than 25 life-changing medicines to treat, prevent and transform conditions that impact millions of people and are rapidly growing our portfolio through research, development and external collaborations.
Latest News
Some of the content on this page is not intended for users outside the U.S.
More Therapeutic Areas
Virology
We’re building on a legacy of transformation in virology.
Oncology
We’re disrupting the status quo in how cancer treatments are developed by accelerating next-generation therapies, expanding access to care and advancing collaborations.